The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Eli Lilly and Co

NYSE: LLY
Last

(U.S.) $71.91

Today's change0.00 0.00%
Updated May 5 4:04 PM EDT. Delayed by at least 15 minutes.
 

Eli Lilly and Co

NYSE: LLY
Last

(U.S.) $71.91

Today's change0.00 0.00%
Updated May 5 4:04 PM EDT. Delayed by at least 15 minutes.

Eli Lilly and Co closed at (U.S.)$71.91.

Over the last five days, shares have gained 1.03% and 4.23% year to date. Shares have outperformed the S&P 500 by 11.26% during the last year.

Key company metrics

  • Open(U.S.) $0.00
  • Previous close(U.S.) $71.91
  • High--
  • Low--
  • Bid / Ask(U.S.) $68.25 / (U.S.) $74.99
  • YTD % change+4.23%
  • Volume0
  • Average volume (10-day)4,907,458
  • Average volume (1-month)4,201,066
  • Average volume (3-month)4,260,385
  • 52-week range(U.S.) $57.81 to (U.S.) $77.46
  • Beta0.33
  • Trailing P/E35.18×
  • P/E 1 year forward22.75×
  • Forward PEG4.90×
  • Indicated annual dividend(U.S.) $2.00
  • Dividend yield2.78%
  • Trailing EPS(U.S.) $2.04
Updated May 5 4:04 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+11.20%

Based on its net profit margin of 11.20%, Eli Lilly and Co is less effective than other companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.00%Sector:HealthcareIndustry:Pharmaceuticals - Diversified
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2015Q4/2014Q3/2014Q2/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014Jun 30, 201406/30/2014
Revenue4,6455,1214,8764,936
Total other revenue--------
Total revenue4,6455,1214,8764,936
Gross profit3,4523,8683,6093,746
Total cost of revenue1,1931,2531,2671,190
Total operating expense4,1204,7454,3144,049
Selling / general / administrative1,5241,8001,6721,664
Research & development1,0391,1861,2431,195
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)3645061310
Other operating expenses, total--------
Operating income525376562887
Interest income (expense), net non-operating---49-48-45
Gain (loss) on sale of assets--------
Other--------
Income before tax618514656940
Income after tax530429501734
Income tax, total8885155207
Net income530429501734
Total adjustments to net income--------
Net income before extra. items530429501734
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items530429501734
Inc. avail. to common incl. extra. items530429501734
Diluted net income530429501734
Dilution adjustment--------
Diluted weighted average shares1,0671,0701,0741,076
Diluted EPS excluding extraordinary itemsvalue per share0.500.400.470.68
Dividends per sharevalue per share0.500.490.490.49
Diluted normalized EPSvalue per share0.820.810.580.68